From:
`Sent:
`To:
`Cc:
`
`Subject:
`
`Trials <Trials@USPTO.GOV>
`Tuesday, April 19, 2016 3:41 PM
`Frank Calvosa; Trials
`Nick Cerrito; Eric Stops; Evangeline Shih; Lyndsey Przybylski; jvbiernacki@jonesday.com;
`DVARUGHE@skgf.com; FRBall@duanemorris.com; Bradford.Frese@arentfox.com;
`richard.berman@arentfox.com; janine.carlan@arentfox.com; MRuedy@meiplaw.com;
`smaddox@meiplaw.com
`RE: IPRs related to Wockhardt v. Jazz Pharmaceuticals
`
`Counsel,
`
`The Board authorizes the parties to file a joint motion in each case to terminate the proceeding or terminate the
`proceeding as to Petitioner Wockhardt Bio AG, pursuant to 37 C.F.R. § 42.72. The joint motion must: (1) include a brief
`explanation as to why termination is appropriate; (2) identify all defendants in any related district court litigation
`involving Patent No. 8,437,797; and (3) discuss the current status of each such related litigation with respect to each
`party to the litigation.
`
`The joint motion to terminate must be accompanied by a true copy of the parties’ settlement agreement, including any
`collateral agreements referred to in such agreement, as required by 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(b). A
`redacted version of the settlement agreement will not be accepted as a true copy of the settlement agreement. Under
`37 C.F.R. § 42.74(c), the parties must file the confidential settlement agreement electronically in the Patent Review
`Processing System (PRPS) as an exhibit in accordance with the instructions provided on the Board’s website (uploading
`as “Parties and Board Only”). The parties are directed to FAQ G2 on the Board’s website at
`http://www.uspto.gov/ip/boards/bpai/prps.jsp for instructions on how to file their settlement agreement as confidential.
`
`
`
`Thanks,
`Andrew Kellogg,
`Supervisory Paralegal
`Patent Trial and Appeal Board
`USPTO
`andrew.kellogg@uspto.gov
`Direct: 571-272-5366
`
`
`
`From: Frank Calvosa [mailto:FrankCalvosa@quinnemanuel.com]
`Sent: Monday, April 18, 2016 4:50 PM
`To: Trials <Trials@USPTO.GOV>
`Cc: Nick Cerrito <NickCerrito@quinnemanuel.com>; Eric Stops <EricStops@quinnemanuel.com>; Evangeline Shih
`<EvangelineShih@quinnemanuel.com>; Lyndsey Przybylski <lyndseyprzybylski@quinnemanuel.com>;
`jvbiernacki@jonesday.com; DVARUGHE@skgf.com; FRBall@duanemorris.com; Bradford.Frese@arentfox.com;
`richard.berman@arentfox.com; janine.carlan@arentfox.com; MRuedy@meiplaw.com; smaddox@meiplaw.com
`Subject: IPRs related to Wockhardt v. Jazz Pharmaceuticals
`
`
`Dear PTAB,
`
`1
`
`
`Page 1 of 2
`
`JAZZ EXHIBIT 2060
`Amneal Pharms. et al. (Petitioner) v. Jazz Pharms., Inc. (Patent Owner)
`Case IPR2015-00546
`
`

`
`
`
`We write on behalf of Patent Owner, Jazz Pharmaceuticals, Inc. (“Jazz”), regarding IPR2015-
`00545, IPR2015-00546, IPR2015-00547, IPR2015-00548, IPR2015-00551, IPR2015-00554,
`IPR2015-01813, IPR2015-01814, IPR2015-01815, IPR2015-01816, IPR2015-01818, IPR2015-
`01820, and IPR2016-00370.
`
`
`We write to respectfully request authorization to file joint motions to terminate the proceedings
`in IPR2015-01813, -01814, -01815, -01816, -01818, -01820, and IPR2016-00370 and joint
`motions to terminate the proceedings with respect to Petitioner Wockhardt Bio AG
`(“Wockhardt”) in IPR-2015-00545, -00546, -00547, -00554, -00548, and -00551. Jazz and
`Wockhardt have entered into a confidential settlement agreement. Wockhardt does not oppose
`this request.
`
`
`Jazz and Wockhardt are available to discuss this issue with the Board tomorrow afternoon, if
`necessary. Counsel for Petitioners are copied on this email.
`
`
`Best regards,
`
`Frank Calvosa
`
`2
`
`Page 2 of 2